For years, glycosylation has been recognized as a pivotal modulator of protein localization and function, influencing everything from cell-cell communication to immune recognition. Unexpectedly, this research identifies that small RNAs themselves undergo N-glycosylation at a unique RNA base, 3-(3-amino-3-carboxypropyl) uridine (acp³U). This finding challenges the traditional dogma that RNA modifications merely Fine-tune RNA stability or translation, instead assigning a critical, previously undiscovered immunomodulatory function to RNA glycosylation.

The team’s experiments reveal that when these N-glycans are enzymatically removed from glycoRNAs isolated from both human and mouse cell cultures as well as from circulating extracellular compartments, a robust innate immune activation ensues. This response is characterized by a surge in type I interferons, molecules central to antiviral defenses and inflammatory pathways. Strikingly, this immune activation relies heavily on Toll-like receptor 3 (TLR3) and Toll-like receptor 7 (TLR7), classical sensors of viral RNA located within the endosomal compartment.

Delving deeper, the researchers probed the functional consequences of RNA glycosylation in the context of apoptotic cell clearance, a physiological process crucial for tissue homeostasis. Apoptotic cells expose small glycoRNAs on their surfaces; these N-glycans effectively cloak the immunogenic acp³U modification on the RNA, preventing recognition by efferocytes—specialized phagocytic cells tasked with engulfing dead cells without provoking inflammation. When N-glycans are removed, these apoptotic cells inappropriately activate endosomal RNA sensors, leading to unwarranted inflammatory signaling that could contribute to autoimmune pathogenesis.

Mechanistically, the study establishes that N-glycans act as a biochemical barrier, shielding the hypermodified uracil base acp³U on glycoRNAs from detection by innate immune receptors. The immunostimulatory potential of acp³U becomes unmasked only upon de-N-glycosylation, suggesting a direct interplay between RNA glycosylation status and immune sensor accessibility. This molecular camouflage elegantly explains how glycoRNAs can localize to cellular surfaces and navigate the endosomal environment without precipitating autoinflammatory responses.

A critical validation of this mechanism comes from the genetic deletion of DTWD2, an enzyme responsible for the synthesis of the acp³U modification. Cells lacking DTWD2 fail to activate innate immune signaling in response to de-N-glycosylated RNAs and apoptotic cells, underscoring that acp³U is indispensable for immune recognition in this context. Furthermore, synthetic RNAs engineered to contain acp³U and lacking N-glycans are sufficient to potently stimulate innate immune pathways, confirming the causative role of this RNA base modification in immune activation.

Beyond deepening fundamental RNA biology, these findings have profound implications for understanding and potentially manipulating immune evasion mechanisms. The discovery of RNA N-glycosylation as an immunological “off switch” that prevents self-RNA from triggering innate sensors reveals a molecular safeguard against autoimmune inflammation. Dysregulation of this process may underlie pathologies where apoptosis and immune clearance balance is disturbed, such as systemic lupus erythematosus and other chronic inflammatory diseases.

The existence of glycoRNAs on cell surfaces and in extracellular compartments adds a new layer of complexity to the landscape of glycosylation and innate immunity. Not only proteins but also small RNAs are subject to sophisticated post-transcriptional modifications that dictate their immunological fate. This paradigm shift forces a reconsideration of how RNA modifications and glycosylation collectively shape host defense and self-tolerance.

From a therapeutic perspective, the pathway identified offers exciting avenues for intervention. Targeting the enzymatic machinery responsible for RNA glycosylation or the recognition of acp³U-modified RNA could yield novel strategies to modulate immune responses. For instance, suppressing aberrant immune activation in autoimmunity or enhancing antiviral immunity through controlled exposure of acp³U-containing RNAs might become feasible.

Moreover, the involvement of Toll-like receptors 3 and 7 situates this glycoRNA-centric mechanism in the broader context of viral sensing and innate immune surveillance. Since these receptors detect viral RNA patterns, the masking of endogenous RNA signatures by N-glycans prevents the immune system from mistaking self for non-self. This has striking evolutionary and biomedical relevance, highlighting a refined molecular interplay between host and pathogen signals.

In summary, this pioneering research delineates a previously unappreciated role of RNA N-glycosylation in immune regulation. By concealing an immunogenic modified base, glycoRNAs evade innate immune detection and facilitate silent apoptotic cell clearance, preserving tissue homeostasis. This advance not only expands the known functions of glycosylation and RNA modifications but also sets the stage for novel insights into immunity, inflammation, and potential therapeutic innovation.

The convergence of RNA biology, glycobiology, and immunology exemplified in this study underscores the multidimensional nature of cellular regulation. Future research will undoubtedly explore the full repertoire of glycoRNA modifications, their enzymatic regulators, and their impact across diverse physiological and pathological contexts. This breakthrough reinvigorates the quest to understand how chemical modifications sculpt biomolecule function and immune interactions at the most fundamental levels.

Subject of Research: N-glycosylation of small RNAs and its role in innate immune evasion and apoptotic cell clearance.

Article Title: RNA N-glycosylation enables immune evasion and homeostatic efferocytosis.

Article References:
Graziano, V.R., Porat, J., Ah Kioon, M.D. et al. RNA N-glycosylation enables immune evasion and homeostatic efferocytosis. Nature (2025). https://doi.org/10.1038/s41586-025-09310-6

Image Credits: AI Generated

RNA, or ribonucleic acid, is a ubiquitous biomolecule found across all domains of life, including viruses, bacteria, and eukaryotic organisms. For decades, immunologists have grappled with the paradox that although viral RNAs trigger robust immune activation, our own cellular RNAs, which are abundant both inside the cell and in extracellular environments during cell turnover, generally do not elicit such responses. This conundrum poses fundamental questions about autoimmunity and immune homeostasis, the answers to which are now partially illuminated by the novel discovery of RNA glycosylation.

The immune system’s ability to distinguish self from non-self RNA is vital to prevent inappropriate inflammation and tissue damage. Viral and bacterial RNAs are often “naked,” meaning exposed without molecular modifications, which leads to their recognition by pattern recognition receptors, such as toll-like receptors and RIG-I-like receptors, in immune cells. These receptors detect pathogen-associated molecular patterns (PAMPs) inherent to foreign RNA and trigger inflammatory signaling cascades. However, endogenous RNAs avoid activation of these pathways, prompting scientists to suspect the presence of molecular shields that mask them from immune sensors.

Through a collaborative effort led by immunologist Vijay Rathinam at the University of Connecticut School of Medicine and chemical biologist Ryan Flynn at Boston Children’s Hospital, the investigative team verified that human cells modify a subset of surface-exposed RNA molecules by attaching sugar moieties in a process termed N-glycosylation of RNA. This glycosylation effectively renders the self-RNA invisible to immune sentinels. Using state-of-the-art biochemical purification and sequencing techniques, the researchers isolated glycoRNAs from human cells and plasma, then enzymatically removed the sugar modifications to experimentally observe the immune consequences.

Remarkably, when the sugar groups were enzymatically stripped from glycoRNAs and these de-glycosylated RNAs were reintroduced into culture with immune cells, the immune system mounted a vigorous inflammatory response, indicating that the sugar coats were essential in suppressing immune activation. This experimental manipulation demonstrated causality and firmly established the concept that RNA glycosylation serves as an immune evasion mechanism, distinguishing self from potentially pathogenic non-self RNAs.

Beyond its implications for fundamental immunology, this discovery has profound significance for understanding the maintenance of immune homeostasis during efferocytosis—the process by which dying cells are cleared by phagocytes. Dead and dying cells inevitably release RNA that could act as potent inflammatory stimuli if recognized incorrectly. The glycosylation of RNA on the surface of dying cells acts as a molecular “don’t eat me” or rather “don’t attack me” signal, preventing unnecessary immune activation and collateral tissue damage during routine cell turnover.

This insight also ignites exciting possibilities for research into the pathogenesis of autoimmune diseases, in which the immune system inexplicably attacks components of the body’s own tissues. Disorders such as systemic lupus erythematosus (lupus) have long been linked to aberrant immune recognition of nucleic acids, but the molecular details had remained elusive. The identification of defective or absent RNA glycosylation in such diseases could explain how self-RNAs become immunogenic, opening avenues for targeted therapeutic interventions designed to restore or mimic this glyco-modification and thereby reinstate immune tolerance.

Technically, the study employed rigorous experimental techniques, including glycomics analyses, RNA sequencing, and immune cell co-culture assays, to dissect the biochemical nature of glycoRNAs and their immunological impact. Lead author Vincent Graziano, a doctoral student in Rathinam’s laboratory, employed enzymatic deglycosylation to remove N-linked sugars, providing the crucial functional validation that sugar moieties shield RNA from immune recognition. These experimental approaches underscore the intricate interplay between chemical modifications and immune responses at a molecular level.

Importantly, the researchers contextualize RNA glycosylation within a broader framework of glycobiology, a field traditionally focused on protein and lipid glycosylation, revealing a surprising new dimension wherein RNA itself is a substrate for glycan attachment. This expands our understanding of molecular diversity and regulation in cell biology and immunology, suggesting that glycoRNAs might serve unrecognized roles beyond immune evasion, perhaps in cell signaling or intercellular communication.

The study’s implications extend into the realm of infectious diseases as well. Since many viruses rely on naked RNAs to alert and subvert host immunity, understanding how self-RNA is masked may illuminate viral strategies that mimic or evade host glycosylation patterns. Furthermore, this knowledge can be harnessed in the design of RNA-based therapeutics or vaccines, ensuring that therapeutic RNAs do not inadvertently activate immune responses, thereby improving their safety and efficacy.

This research was a multidisciplinary collaboration, combining expertise in immunology, molecular biology, and chemical glycobiology, highlighting the importance of integrative approaches to unravel complex biological phenomena. Funding support from numerous institutions, including the National Institutes of Health and several foundations dedicated to immunological research, underscores the high scientific and potential clinical impact of these findings.

In summary, the discovery of RNA N-glycosylation as a key modulator of immune recognition represents a paradigm shift in our comprehension of self versus non-self discrimination at the molecular level. By cloaking self-RNA in sugar modifications, cells elegantly avoid unwarranted immune activation, maintaining balance and preventing inflammatory diseases. This breakthrough not only advances fundamental immunology but also paves the way for novel diagnostics and therapies targeting autoimmune conditions and improving RNA-based medical interventions.

Subject of Research: Human tissue samples

Article Title: RNA N-glycosylation enables immune evasion and homeostatic efferocytosis.

News Publication Date: 6-Aug-2025

Web References:
https://www.nature.com/articles/s41586-025-09310-6
http://dx.doi.org/10.1038/s41586-025-09310-6

Keywords: RNA, Immunology, Immune cells, Immune disorders, Autoimmune disorders, Lupus, Molecular biology, RNA structure, Viral RNA